Elite Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	122.89	84.04	56.63	34.16	32.26	25.38
Revenue Growth (YoY)	72.67%	48.42%	65.79%	5.87%	27.11%	41.05%
Cost of Revenue	58.18	43.96	30.27	17.56	17.47	13.51
Gross Profit	64.71	40.09	26.36	16.59	14.8	11.87
Selling, General & Admin	12.19	9	7.15	5.12	4.46	3.32
Research & Development	6.9	7.96	6.88	6.2	4.05	5.11
Operating Expenses	20.95	18.88	15.57	12.63	9.72	9.76
Operating Income	43.77	21.2	10.79	3.97	5.07	2.1
Interest Expense	-0.51	-0.77	-0.59	-1.11	-0.19	-0.26
Interest & Investment Income	0.02	0.02	0.02	0.01	0	0
Other Non Operating Income (Expenses)	-17.93	-18.9	-11.52	0.42	1.43	1.24
EBT Excluding Unusual Items	25.35	1.55	-1.3	3.28	6.3	3.08
Gain (Loss) on Sale of Assets	-	-	-	1	-	0.05
Asset Writedown	-1.6	-1.6	-	-0.29	-	-
Other Unusual Items	-	-	1.76	-	0.86	1.96
Pretax Income	23.75	-0.05	0.46	3.99	7.16	5.09
Income Tax Expense	9.82	4.26	-19.65	0.42	-1.74	-
Net Income	13.92	-4.31	20.11	3.56	8.9	5.09
Net Income to Common	13.92	-4.31	20.11	3.56	8.9	5.09
Net Income Growth	-	-	464.56%	-59.97%	74.87%	-
Shares Outstanding (Basic)	1,069	1,068	1,015	1,013	1,011	943
Shares Outstanding (Diluted)	1,075	1,068	1,023	1,013	1,011	943
Shares Change (YoY)	3.11%	4.40%	1.02%	0.23%	7.17%	-5.06%
EPS (Basic)	0.01	-0.00	0.02	0.00	0.01	0.01
EPS (Diluted)	0.01	-0.00	0.02	0.00	0.01	0.00
EPS Growth	-	-	537.54%	-57.99%	81.05%	-
Free Cash Flow	21.66	5.83	-4.04	-2.4	6.01	2.86
Free Cash Flow Per Share	0.02	0.01	-0.00	-0.00	0.01	0.00
Gross Margin	52.66%	47.70%	46.55%	48.58%	45.86%	46.76%
Operating Margin	35.62%	25.23%	19.05%	11.62%	15.72%	8.29%
Profit Margin	11.33%	-5.13%	35.51%	10.43%	27.58%	20.05%
Free Cash Flow Margin	17.62%	6.94%	-7.14%	-7.02%	18.63%	11.28%
EBITDA	45.4	22.89	12.16	5.23	6.27	3.4
EBITDA Margin	36.94%	27.24%	21.47%	15.32%	19.42%	13.41%
D&A For EBITDA	1.63	1.69	1.37	1.26	1.19	1.3
EBIT	43.77	21.2	10.79	3.97	5.07	2.1
EBIT Margin	35.62%	25.23%	19.05%	11.62%	15.72%	8.29%
Effective Tax Rate	41.36%	-	-	10.64%	-	-
Revenue as Reported	122.89	84.04	56.63	34.16	32.26	25.38

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.